piclidenoson + Placebo
Phase 3Recruiting 0 watching 0 views this week๐ Rising
69
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 24
Phase 35
ApprovedIndication / Disease
Plaque Psoriasis
Conditions
Plaque Psoriasis
Trial Timeline
Jun 1, 2025 โ Jun 1, 2028
NCT ID
NCT06643260About piclidenoson + Placebo
piclidenoson + Placebo is a phase 3 stage product being developed by Can Fite Biopharma for Plaque Psoriasis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06643260. Target conditions include Plaque Psoriasis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
2
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06643260 | Phase 3 | Recruiting |
| NCT04333472 | Phase 2 | Completed |
Competing Products
20 competing products in Plaque Psoriasis